A- A A+

USA. Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder


The Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder provides eligible physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives, who are state licensed and registered by the DEA to prescribe controlled substances, an exemption from certain statutory certification requirements related to training, counseling and other ancillary services (i.e., psychosocial services).

(Office of the Secretary, Department of Health and Human Services, USA, 28.04.2021)


USA. HHS Releases New Buprenorphine Practice Guidelines, Expanding Access to Treatment for Opioid Use Disorder

In an effort to get evidenced-based treatment to more Americans with opioid use disorder, the Department of Health and Human Services (HHS) is releasing new buprenorphine practice guidelines that among other things, remove a longtime requirement tied to training, which some practitioners have cited as a barrier to treating more people. (SAMHSA – Substance Abuse and Mental Health Services Administration, USA, 27.04.2021)


Handbook for Healthcare Executives - Creating a Culture of Safety for Opioid Prescribing

Healthcare executives have an important role in creating a culture for safer opioid prescribing. This handbook contains insights and advice from healthcare executives and quality improvement leaders from four different health systems representing urban, suburban and rural settings. They share their experiences engaging internal and external stakeholders, working across interdisciplinary teams, leveraging data to inform efforts, implementing training and educational efforts, and much more. (CDC – Centers for Disease Control und Prevention, Mai 2021)


Clinical Practice Guideline on Pharmacological and Psychological management of adult patients with Schizophrenia Spectrum Disorders and a comorbid substance use. 

Arranz B, Garriga M, Bernardo M, Gonzalez-Pinto A, Arrojo M, Torrens M, Tirado-Muñoz J, Fonseca F, Saiz PA, Florez G, Goikolea JM, Zorrilla I, Cunill R, Castells X, Becoña E, Lopez A, San L. 

Adicciones. 2021 Mar 11;0(0):1504. English, Spanish. doi: 10.20882/adicciones.1504. Epub ahead of print. PMID: 33768260.


Clinical practice guideline on pharmacological and psychological management of adult patients with depression and a comorbid substance use disorder. 

Torrens M, Tirado-Muñoz J, Fonseca F, Farré M, Gonzalez-Pinto A, Arrojo M, Bernardo M, Arranz B, Garriga M, Saiz PA, Florez G, Goikolea JM, Zorrilla I, Cunill R, Castells X, Becoña E, Lopez A, San L. 

Adicciones. 2021 Mar 12;0(0):1559. English, Spanish. doi: 10.20882/adicciones.1559. Epub ahead of print. PMID: 33768269.


Schottland. Medication Assisted Treatment - MAT Standards for Scotland - Access, Choice, Support

Scottish Drugs Deaths Task Force, Interim report On behalf of the MAT Subgroup, March 2021, 

Report prepared by Elinor Dickie, Tracey Clusker, Duncan McCormick, with special thanks to Lindsey Murphy, Austin Smith, Liz Taylor,Karen Mailer& Sara Hafiz


UK. Guidance: Injectable opioid treatment: commissioning and providing services 

Guidance on commissioning and providing injectable opioid treatment for people with opioid dependence who have not responded to oral treatment. (Government UK, Public Health England, 19.03.2021)


Canadian national consensus guidelines for naloxone prescribing by pharmacists. 

Tsuyuki RT, Arora V, Barnes M, Beazely MA, Boivin M, Christofides A, Patel H, Laroche J, Sihota A, So R. 

Can Pharm J (Ott). 2020 Aug 26;153(6):347-351. doi: 10.1177/1715163520949973. PMID: 33282024; PMCID: PMC7689616.


USA. Use of Medication-Assisted Treatment in Emergency Departments

This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation. (Substance Abuse and Mental Health Administration (SAMHSA), USA, 05.02.2021)


We're in this together - All about treatment for opioid dependence from people who have lived it - Client guide

(European Network of People who Use Drugs (EuroNPUD), 30.01.2021)


The Chinese version of obsessive compulsive drug use scale: validation in outpatient methadone maintenance treatment program. 

Gong H, Zhang Y, Ren Q, Zhou Z, Zhou H, Sun X, Zhang C, Voon V, Zhao M, Yu S. 

BMC Psychiatry. 2020 Sep 25;20(1):465. doi: 10.1186/s12888-020-02843-2. PMID: 32977774; PMCID: PMC7517618.


The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder - 2020 Focused Update

The ASAM National Practice Guideline 2020 focused update is intended to inform and empower clinicians, health system administrators, criminal justice system administrators, and policymakers who are interested in implementing evidence-based practices to improve outcomes for individuals with OUD. This is especially critical in the context of the ongoing COVID-19 emergency, which threatens to curtail patient access to evidence-based treatment.  

The document is an update to the previous NPG released in 2015 and includes major revisions to 35 existing recommendations, along with the addition of 13 new recommendations.

This focused update was developed over the course of 14 months with consensus from an independent committee of experts and the use of a rigorous RAND/RAM methodology facilitated by researchers from Research Triangle Institute (RTI).


EMCDDA operating guidelines for the risk assessment of new psychoactive substances


The purpose of these guidelines is to ensure compliance with the scope and requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) in respect to the risk assessment procedure for and reporting on new psychoactive substances.

To operationalise the technical aspects of the risk assessment, the guidelines are supported by a set of Guidance notes developed by the EMCDDA. The Guidance notes will be adapted as required in order to reflect developments in the field of new psychoactive substances and risk assessment. (EMCDDA, Lissabon, Dezember 2020)


Schottland. Standards for Scotland: Access - Choice – Support -- Consultation on the standards&implementation

Medication Assisted Treatment (MAT), Schottland, November 2020


Prevention and Treatment of HIV Among People Living with Substance Use and/or Mental Disorders

This guide reviews interventions for people living with substance use and mental disorders who are at risk for or living with HIV. Selected interventions are in alignment with goals of the federal “Ending the HIV Epidemic: A Plan for America” (EHE) initiative.

SAMHSA – Substance Abuse and Mental Health Services Administration, Rockville, USA

Publication ID PEP20-06-03-001, Publication Date November 2020


Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians. 

Abraham GM, Obley AJ, Humphrey LL, Qaseem A. World 

Ann Intern Med. 2020 Oct 6. doi: 10.7326/M19-3860. Epub ahead of print. PMID: 33017566.


Effects of the new prescribing standards in British Columbia on consumption of opioids and benzodiazepines and z drugs. 

Crabtree A, Rose C, Chong M, Smolina K. 

Can Fam Physician. 2019;65(5):e231-e237.


Changing Outdated Methadone Regulations That Harm Pregnant Patients 

McCarthy JJ, Jones HE, Terplan M, Rudolf VP, von Klimo MC. 

[published online ahead of print, 2020 Aug 18]. J Addict Med. 2020;10.1097/ADM.0000000000000720. doi:10.1097/ADM.0000000000000720



EMCDDA/ECDC. Call for expressions of interest: Phase 1 of collection of models of good practice - Joint ECDC/EMCDDA PWID Guidance (2011) update
The joint ECDC & EMCDDA guidance on Prevention and control of infectious diseases among people who inject drugs (2011) is currently being updated. In addition to ongoing systematic reviews of peer-reviewed literature, a collection of models of good practice has been initiated by the two agencies, that should add practice-based evidence derived from interventions implemented in real-life, European settings.
We are inviting applications to report models of good practice targeting PWID population. (ECDC- European Centre for Disease Prevention and Control, August 2020)


USA. Treatment of Stimulant Use Disorders

This guide supports health care providers, systems, and communities seeking to treat stimulant use disorders. It describes relevant research findings, examines best practices, identifies knowledge gaps and implementation challenges, and offers useful resources. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, Juni 2020)


Schweiz. Medizinische Empfehlungen für Opioidagonistentherapie (OAT) bei Opioidabhängigkeits-Syndrom 2020 

Erstellt durch Mitglieder der Schweizerischen Gesellschaft für Suchtmedizin, SSAM 

Verfalldatum: Januar 2025 


UNODC – WHO. International standards for the treatment of drug use disorders: revised edition incorporating results of field-testing. 

Geneva: World Health Organization and United Nations Office on Drugs and Crime; 2020. License: CC BY-NC-SA 3.0 IGO


Canadian Guidelines on Opioid Use Disorder Among Older Adults.

Rieb LM, Samaan Z, Furlan AD, Rabheru K, Feldman S, Hung L, Budd G, Coleman D.

Can Geriatr J. 2020 Mar 30;23(1):123-134. doi: 10.5770/cgj.23.420. 


Irland. Clinical guidelines for opioid substitute treatment. Guidance document for OST in the hospital setting (PDF) 

Appropriate policies and standard operating procedures for the provision of in-patient Opioid Substitution Treatment (OST) is paramount to patient safety when treating a person with an opioid dependency (prescribed or unprescribed). (Health Service Executive, Irland, 2020)


USA. National Practice Guideline for the treatment of opioid use disorder

This Practice Guideline was developed for the treatment of opioid use disorder and the prevention of opioid overdose-related death

ASAM - American Society of Addiction Medicine, März 2020


USA. Opioid Use Disorder: Treatment Guidelines for Nonspecialists

To expand access to treatment for OUD, the Substance Use Guideline Committee of the New York State Department of Health AIDS Institute (NYSDOH AI) has just published the Treatment of Opioid Use Disorder guideline, designed for use by primary care and other clinicians who don't specialize in the management of substance use disorders. The guideline is applicable in clinical care of OUD in primary care practice not only in New York but throughout the United States. (NEW YORK STATE DEPARTMENT OF HEALTH AIDS INSTITUTE, August 2019)


Schweiz. Genuss, Suchtmittelkonsum und Abhängigkeiten in Alterszentren

Musterkonzept «Genuss, Suchtmittelkonsum und Abhängigkeiten in Alterszentren»: Wie gelingt die Früherkennung und die Betreuung von Suchtbetroffenen im Pflegealltag? Dieses Musterkonzept (pdf, 28S.) zeigt praktische Herangehensweisen auf und dient Institutionen und Mitarbeitenden aus dem Pflegebereich als Grundlage für die Entwicklung eigener Lösungen. Es wurde vom Fachverband Sucht in Zusammenarbeit mit Infodrog, dem Gustav Benz Haus sowie weiteren Expertinnen und Experten aus der Alterspflege und der Suchthilfe entwickelt. (30.04.2019)


Drug-Induced Liver Injury EASL Guideline

Idiosyncratic (unpredictable) Drug-Induced Liver Injury is one of the most challenging liver disorders faced by hepatologists. This happens because of the myriad of drugs used in clinical practice. Also due to the available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers.  Therefore, this makes the diagnosis of Drug-Induced Liver Injury an uncertain process. One that requires a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe. It can lead to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed.
This Clinical Practice Guideline summarizes the available evidence on risk factors, diagnosis, management, risk minimization strategies for Drug-Induced Liver Injury. (EASL - The European Association for the Study of the Liver, April 2019) 


ACP issues guideline for testosterone treatment in adult men with age-related low testosterone

ACP’s recommendations include treating for sexual dysfunction only, discontinuing treatment if sexual function does not improve, and not initiating treatment for other reasons

Philadelphia, January 7, 2020 – Physicians should prescribe testosterone for men with age-related low testosterone only to treat sexual dysfunction, the American College of Physicians (ACP) says in a new evidence-based clinical practice guideline published today in Annals of Internal Medicine. (American College of Physicians (ACP), 07.01.2020)


Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians.

Qaseem A, Horwitch CA, Vijan S, et al, for the Clinical Guidelines Committee of the American College of Physicians. 

Ann Intern Med. 2020;172:126–133. [Epub ahead of print 7 January 2020]. doi.org/10.7326/M19-0882